Disaggregated Revenues

9 Months Ended

Sep. 30, 2023

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
	(unaudited)				(unaudited)
Net product sales
Qelbree	$	37,081	$	18,326	$	93,840	$	37,708
GOCOVRI	32,889		27,878		87,650		75,179
Oxtellar XR	29,644		30,528		82,359		88,007
Trokendi XR	20,625		69,599		74,734		204,033
APOKYN	21,510		18,261		56,324		57,156
Other(1)	7,255		8,132		23,008		23,564
Total net product sales	$	149,004	$	172,724	$	417,915	$	485,647
Royalty revenues	4,876		4,629		25,292		14,263
Total revenues	$	153,880	$	177,353	$	443,207	$	499,910

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

The decrease in Trokendi XR net product sales for the three and nine months ended September 30, 2023, compared to the same period in 2022 was primarily attributable to the loss of exclusivity with generic entrants in January 2023.

The following table shows the percentage of net product sales to total net product sales:

	Percentage of Net Product Sales
	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Qelbree	25%	11%	22%	8%
GOCOVRI	22%	16%	21%	15%
Oxtellar XR	20%	18%	20%	18%
Trokendi XR	14%	40%	18%	42%
APOKYN	14%	10%	13%	12%
Other(1)	5%	5%	6%	5%
Total	100%	100%	100%	100%

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total net product sales and collectively accounted for more than 70% of our total net product sales for the three and nine months ended September 30, 2023 and 2022.

The Company recognized noncash royalty revenue of $4.0 million for the nine months ended September 30, 2023. The Company recognized noncash royalty revenue of $2.5 million and $7.2 million for the three and nine months ended September 30, 2022, respectively. Refer to Note 15, Commitments and Contingencies.